Eudaimonia Partners’s Alimera Sciences ALIM Stock Holding History

Eudaimonia Partners’s Portfolio ALIM Stock Details ALIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-33	Closed	–	–	1433
2021 Q1	$0	Buy	+33	New	+$270	﹤0.01%	1668

Other funds holding ALIM

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

CCPM

Cooper Creek Partners Management New York $2.92B AUM 30.49% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Eudaimonia Partners's ALIM Position: Q2 2021 in Review

Eudaimonia Partners sold out of Alimera Sciences (ALIM) in Q2 2021, closing a stake of 33 shares.

Eudaimonia Partners first reported a position in ALIM in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 25 funds tracked by Wall St. Rank hold ALIM as of Q2 2021.

Eudaimonia Partners reported no remaining Alimera Sciences position as of Q2 2021 after selling out during the quarter.
Eudaimonia Partners sold 33 Alimera Sciences shares in Q2 2021.
Eudaimonia Partners first reported a position in Alimera Sciences in Q1 2021 and held it in 1 quarter.
Eudaimonia Partners's Alimera Sciences position peaked at $0 in Q1 2021.
25 funds tracked by Wall St. Rank held Alimera Sciences as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.